Latest action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Speeds up development and approval of new medical treatments and cures.
The problem
Current drug development takes many years and costs billions. Patients wait for new treatments. The process may slow innovation in medicine.
The proposal
Changes federal drug approval rules to make testing and development of new treatments faster. Updates how medicines get reviewed and approved.
The impact
Drug companies, patients seeking treatments, FDA, and healthcare system all affected. May speed up access to new medicines.
Patients with serious diseases could get new treatments sooner. This could save lives and reduce suffering for people who need experimental drugs.
Faster approval may encourage pharmaceutical companies to invest in new treatments. This could lead to more cures and breakthroughs.
Streamlined approval could reduce development costs and timelines. Companies might invest more in research and create more jobs.
Faster U.S. approval could help American drug companies compete internationally. This supports the economy and innovation leadership.
Rushing testing might miss side effects or long-term dangers. Patients could be harmed if treatments aren't thoroughly tested.
Streamlined rules might reduce FDA's ability to catch problems. Companies could cut corners in testing.
Companies might charge more for new drugs if approval is faster. Patients and insurance companies could pay significantly higher prices.
Expensive new drugs approved quickly might only be available to wealthy patients. This could increase healthcare inequality.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
No lobbying disclosures matched this bill.